Intercure annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Intercure R&D Spending Growth & History (INCR)
Intercure's r&d spending was ₪390,000 for fiscal 2025.
View full Intercure company overviewIntercure annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | ₪390,000 | −₪24,000 | −5.80% |
| 2024 | 2024-12-31 | ₪414,000 | ₪26,000 | +6.70% |
| 2023 | 2023-12-31 | ₪388,000 | −₪244,000 | −38.61% |
| 2022 | 2022-12-31 | ₪632,000 | −₪603,000 | −48.83% |
| 2021 | 2021-12-31 | ₪1.2M | −₪341,000 | −21.64% |
| 2020 | 2020-12-31 | ₪1.6M | −₪134,000 | −7.84% |
| 2019 | 2019-12-31 | ₪1.7M | — | — |
Intercure r&d spending trends
Over the last five fiscal years, Intercure's r&d spending decreased from ₪1.6M to ₪390,000, a change of −₪1.2M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Intercure source filings ↗Community posts
InterCure resolves Nasdaq minimum-bid-price deficiency
InterCure ($INCR) received written confirmation that it has regained compliance with Nasdaq’s minimum-bid-price requirement. Its shares had closed at or above $1 for ten consecutive business days, allowing Nasdaq to close the specific defic ...